Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Unblinding Plans For COVID-19 Vaccine Trials Take Roads Less Travelled

Executive Summary

Pfizer relies on investigators to determine when prioritization recommendations apply, Moderna offers unblinding to everyone.

You may also be interested in...

Filling COVID-19 Vaccine Data Gaps Will Take Time

Timeline for getting data on COVID-19 vaccines ability to prevent transmission is likely pushed due to the decision not to proceed with a NIH study on the topic. CDC warns that it will take more time than people expect to get other key data points filled in and vaccine regimen plans shouldn’t change without such data.

Placebo-Unblinding Should Be Uniform Across COVID Vaccine Trials, Advisory Committee Says

US FDA’s outside advisors say Moderna should offer vaccine to placebo-arm patients when they are eligible, the same plan adopted for the Pfizer/BioNTech COVID-19 vaccine.

Pfizer Doesn’t Like Crossover Design For Placebo Patients In COVID-19 Vaccine Trial

Only vaccinating the placebo group would be much easier once the US FDA grants an EUA for its coronavirus vaccine, Pfizer says.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts